Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and ...
One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback